Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Ceapro Inc. (CRPOF : OTC)
 
 • Company Description   
Ceapro Inc. is a biotechnology company. The company develop and commercialize ingredients for human and animal health markets. Its product pipeline includes botanical product & oat product. The company's technology consists of PGX Technology. Ceapro Inc. is headquartered in Edmonton, Canada.

Number of Employees:

 
 • Price / Volume Information   
Yesterday's Closing Price: $0.45 Daily Weekly Monthly
20 Day Moving Average: 15,042 shares
Shares Outstanding: 77.69 (millions)
Market Capitalization: $35.00 (millions)
Beta: 1.85
52 Week High: $0.59
52 Week Low: $0.33
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week 7.54% 17.75%
12 Week 25.14% 40.64%
Year To Date -6.15% 14.66%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
7824 51 Avenue NW
-
Edmonton,A0 T6E 6W2
CAN
ph: 780-421-4555
fax: 780-421-1320
czo@jtcir.com http://www.ceapro.com
 
 • General Corporate Information   
Officers
Gilles Gagnon - Chief Executive Officer and President
Glenn Rourke - Chairman
Stacy Prefontaine - Chief Financial Officer
Leoni DeJoya - Vice President
Marc Morisset - Director

Peer Information
Ceapro Inc. (CORR.)
Ceapro Inc. (RSPI)
Ceapro Inc. (CGXP)
Ceapro Inc. (BGEN)
Ceapro Inc. (GTBP)
Ceapro Inc. (RGRX)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 149907107
SIC: 2834
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/22
Next Expected EPS Date: 08/25/22
Share - Related Items
Shares Outstanding: 77.69
Most Recent Split Date: (:1)
Beta: 1.85
Market Capitalization: $35.00 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $ Payout Ratio: 0.00
Number of Estimates in the Fiscal Year Consensus: Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/25/22  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: 9.01
PEG Ratio: -
Price Ratios
Price/Book: 1.61
Price/Cash Flow: 9.29
Price / Sales: 2.35
EPS Growth
vs. Year Ago Period: 100.00%
vs. Previous Quarter: 100.00%
Sales Growth
vs. Year Ago Period: 31.21%
vs. Previous Quarter: 72.40%
ROE
03/31/22 - 16.25
12/31/21 - 10.92
09/30/21 - 6.23
ROA
03/31/22 - 14.00
12/31/21 - 9.37
09/30/21 - 5.25
Current Ratio
03/31/22 - -
12/31/21 - 12.06
09/30/21 - 8.07
Quick Ratio
03/31/22 - -
12/31/21 - 10.37
09/30/21 - 7.03
Operating Margin
03/31/22 - 23.11
12/31/21 - 16.54
09/30/21 - 9.55
Net Margin
03/31/22 - 23.11
12/31/21 - 16.54
09/30/21 - 9.55
Pre-Tax Margin
03/31/22 - -
12/31/21 - 15.23
09/30/21 - 9.85
Book Value
03/31/22 - -
12/31/21 - 0.28
09/30/21 - 0.27
Inventory Turnover
03/31/22 - -
12/31/21 - 5.61
09/30/21 - 6.15
Debt-to-Equity
03/31/22 - -
12/31/21 - 0.00
09/30/21 - 0.00
Debt-to-Capital
03/31/22 - -
12/31/21 - 0.00
09/30/21 - 0.00
 

Powered by Zacks Investment Research ©